Piper Sandler lowered the firm’s price target on Aslan Pharmaceuticals to $3 from $4 and keeps an Overweight rating on the shares. Aslan completed enrollment of 300 moderate-to-severe atopic dermatitis patients in the Phase IIb TREK-AD study of eblasakimab with top-line data expected in early July, the analyst tells investors in a research note. The analyst cites dilution from the private placement for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASLN:
- ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
- Aslan Pharmaceuticals price target lowered to $4.50 from $7 at H.C. Wainwright
- Aslan Pharmaceuticals announces $20M private placement
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M